Life Sciences MoForum 2024 | San Diego: The State of the Life Sciences Industry
- On September 24, 2024, Morrison Foerster hosted another installment of its premier MoForum series at the firm’s San Diego office. Mayor Todd Gloria shared his vision for San Diego’s commitment to the industry. The event featured expert panel discussions on cutting-edge scientific developments, market... ›
- - Corporate + Venture Capital, Employment, Financing, Global, Intellectual Property, Litigation, Privacy + Data Security, Regulatory, Startup
When Your Life Sciences Are on the Line: Protecting Your Company’s Most Valuable Asset: Trade Secrets
By: Kate Driscoll, Nathaniel R. Mendell and Jim Krenn
MoFo partners Kate Driscoll and Nate Mendell launched the MoFo life sciences podcast When Your Life Sciences Are on the Line this week, and Episode 1 is now available. The podcast features interviews with legal experts who share insights and advice you just might... › Top Three IP Issues for AgTech Startups
By: Matthew A. Ferry and Edith A. Pierre-Jerome Ph.D.
Innovation, agriculture, and technology took center stage at San Diego’s first AgTech Hackathon. The event took place October 21 – 23 in the city of Escondido, a key farming hub in San Diego County looking to attract agtech startups to the region. The event... ›Navigating Transaction and Licensing Issues in a COVID-19 World and Raising Angel Investments
By: Jim Krenn, Matt Karlyn and Michael Ward Ph.D.
Session 2 of the GSAS Harvard Biotech Club and Morrison & Foerster course on Legal Topics for Scientists, Entrepreneurs, and Start Ups was led by Transactions and Licensing partner Matt Karlyn and focused on how to navigate commercial life sciences transactions and licensing issues in... ›GSAS Harvard Biotech Club and Morrison & Foerster’s New Course
By: Andrew Boyd, Alfredo B. D. Silva, Anita Choi and Michael Ward Ph.D.
MoFo & GSAS Harvard Biotech Club’s new course, “ Legal Topics for Scientists, Entrepreneurs, and Start Ups ,” started on November 11, with more than 100 life sciences graduate students, post-docs, and industry professionals. The Harvard Biotech Club is a student organization that seeks to... ›Life Sciences Startup: Top Things to Keep in Mind About Formation and License Agreements
By: Steve Rowles, Matt Karlyn and Michael Ward Ph.D.
During our fifth Patent Law Course session offered by Morrison & Foerster and GSAS Harvard Biotech Club , Steve Rowles, firmwide co-chair of the Emerging Companies & Venture Capital Group , chair of MoFo’s San Diego Corporate Group, and managing partner of the San... ›Morrison & Foerster Expands Corporate Capabilities Adding New Corporate Co-Chair Mitchell Presser
By: Mitchell S. Presser
Morrison & Foerster is pleased to announce the continued expansion of its New York office and global Corporate Department capabilities with the arrival of corporate partner Mitchell Presser. He joins the firm as a partner in its Mergers + Acquisitions and Private Equity Investments + Buyouts practices and... ›The New ABC's: Artificial Intelligence, Blockchain and How Each Compliments the Other
By: Vivian L. Hanson and Lee Adam Nisson
Artificial intelligence (AI) and blockchain technology are two novel innovations that offer the opportunity for us to move beyond our legacy systems and streamline enterprise management and compliance in ways previously unimaginable. Each technology augments the strengths and tempers the weaknesses of the other.... ›An Easier Road to a Hong Kong Listing for Biotech Companies
By: Janet Xiao Ph.D. and Jie Zhou Ph.D.
In June 2017, the Hong Kong Stock Exchange (“HKEx”) initiated a holistic review of the Hong Kong listing regime to enhance its overall competitiveness against other major global listing venues, in particular to attract companies from emerging and innovative sectors. During this review, the... ›Startup diligence is more than ‘basic IP diligence’
In technology-based startup companies, the strength and integrity of a company’s IP portfolio is a key indicator of its enterprise value. Wise investors closely scrutinize the IP of their targets by doing basic IP diligence. But doing only basic diligence can leave investors blind... ›